Which medication is indicated to stimulate appetite in patients undergoing chemotherapy?

Dronabinol is indicated for stimulating appetite in patients undergoing chemotherapy due to its active ingredient, delta-9-tetrahydrocannabinol (THC), which is a cannabinoid. THC interacts with the endocannabinoid system in the brain, which plays a significant role in appetite regulation. In cancer patients, especially those undergoing chemotherapy, appetite loss can lead to weight loss and malnutrition, negatively impacting their overall health and quality of life. Research has shown that dronabinol can effectively increase appetite and help to reduce nausea, making it a valuable option for addressing these issues in this patient population.

The other medications listed do not have a primary indication for stimulating appetite in the context of chemotherapy. Fluoxetine is primarily an antidepressant and does not directly enhance appetite. Gabapentin is typically used for neuropathic pain and seizure control, and while it may have some effects on mood and anxiety, it is not indicated for appetite stimulation. Clozapine, an antipsychotic used for treatment-resistant schizophrenia, may cause weight gain as a side effect but is not specifically prescribed to increase appetite in cancer patients. Therefore, dronabinol stands out as the appropriate choice for appetite stimulation in this context.